Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study

2011/12/29 by Maria Maersk, M Maersk, Anita Belza +10 · 28 citations
Medicine · Nursing · #Diet, Metabolism, and Disease #Biochemical Analysis and Sensing Techniques #Food composition and properties

paper · pdf · doi:10.3945/ajcn.111.022533

Cited by

• Non-pharmacological treatment of MASLD
• Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats
• Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome
• Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. [europepmc]
• Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. [europepmc]
• High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. [europepmc]
• Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. [europepmc]
• New dynamics in global obesity facing low- and middle-income countries. [europepmc]
• Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: health be damned! Pour on the sugar. [europepmc]
• Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. [europepmc]
• Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. [europepmc]
• Sugar consumption, metabolic disease and obesity: The state of the controversy. [europepmc]
• Fructose and Cardiometabolic Health: What the Evidence From Sugar-Sweetened Beverages Tells Us. [europepmc]
• Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. [europepmc]
• Sweetening of the global diet, particularly beverages: patterns, trends, and policy responses. [europepmc]
• Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. [europepmc]
• Fructose metabolism and metabolic disease. [europepmc]
• Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. [europepmc]
• Dietary carbohydrates: role of quality and quantity in chronic disease. [europepmc]
• Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. [europepmc]
• Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. [europepmc]
• Sugary drink consumption and risk of cancer: results from NutriNet-Santé prospective cohort. [europepmc]
• Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial. [europepmc]
• Dietary Fructose and the Metabolic Syndrome. [europepmc]
• An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. [europepmc]
• Current treatment paradigms and emerging therapies for NAFLD/NASH. [europepmc]
• Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. [europepmc]
• Molecular aspects of fructose metabolism and metabolic disease. [europepmc]